Past Grants:    Development of a Childhood Vaccine for Respiratory Syncytial Virus (2009-2012)

                          Improving Early Childhood Vaccines (2005-2008)​​

Past Grants:   Psoriatic Arthritis Research Program (2003-2014)

                         Peripheral Blood Gene Expression Profiles in Psoriatic Arthritis vs Psoriasis (2008)

                         Interplay Between Skin and Joint Disease: Genetic Marks in Psoriasis and Psoriatic Disease (2008)

                         Genetic Markers of Psoriatic Arthritis (2007)

* Not all grants have been displayed


Dr. Dafna Gladman

Toronto Western Research Institute

Psoriatic Arthritis Research Program (2014-2017)

Psoriatic disease is an immune-mediated disease which includes cutaneous psoriasis and psoriatic arthritis.  Dr. Dafna Gladman founded the Psoriatic Arthritis Research Program (PsARP) with a vision to assist and oversee research projects that can deliver real results to patients. The foundation for PsARP is their large cohort of patients upon which all research projects are made possible.  The program intends to improve the lives of those afflicted with psoriatic disease by leading both research and clinical efforts in better understanding disease etiology, disease progression, discovery of new treatments, biomarkers, and prevention measures.  The program has changed the medical community’s understanding of psoriatic disease and their research efforts have resulted in improved diagnostics and treatments that have a direct impact on patients with psoriatic disease.  The Foundation has had a long-standing commitment to support PsARP and believe a large amount of their success is due to a dedicated team applying a true “bedside to bench and back to bedside” approach to deliver real results to their patients.

Dr. Andrew Potter

University of Saskatchewan

Development of a Combination Vaccine against Respiratory Syncytial Virus and Parainfluenzavirus (2014-2016)

Respiratory diseases, like respiratory syncytial virus (RSV) and human parainfluenzavirus-3 (hPIV3) are two of the most severe diseases to affect young children.  Vaccinations against these are difficult in infants because their immune system is not well developed at birth, and can’t generate sufficient levels of protective antibodies.  To overcome this barrier, Dr. Potter and his team plan to formulate a vaccine with a strong adjuvant (something that can enhance their immune response) and develop maternal immunizations to enhance the level of antibodies that are transferred from mothers to infants providing protection from disease until their immune systems fully develop.  Furthermore, the goal of Dr. Potter’s research is to develop a combination vaccine, providing protection to young children, against two of the most severe respiratory diseases.  

Dr. Cathy Barr

Toronto Western Research Institute

Functional Annotation of Genetic Variants Contributing to Immune Mediated Diseases (2015-2018)

Immune-mediated diseases (IMDs) are characterized by misregulation of the immune system resulting in tissue and organ damage.  IMDs such as rheumatoid arthritis, ankylosing spondylitis, and lupus are chronic and significantly impact the quality of life for affected individuals.  Genome-wide association studies have identified common changes in regions of DNA in individuals with IMDs.  Many of these changes have been found in regulatory regions of DNA called enhancers which regulate the expression of specific genes.  Because enhancers often regulate the expression of genes that are very far from them, it has been challenging to predict the functional impact of DNA variants within these regions.  Using high-throughput genetic technologies developed in her lab, Dr. Barr will determine the functional impact of DNA variants in enhancers by assessing how variants affect enhancer activity, and ultimately gene expression.  This work will provide insight into which genes are affected, which is crucial to understanding the genetic basis of IMDs, identifying risk factors, and forming the basis for new treatments.